Redx Pharma (GB:REDX) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Redx Pharma’s CFO, Peter Collum, has acquired 59,614 ordinary shares of the company at an average price of 20.87 pence per share, increasing his stake to 0.04% of the issued share capital. This move by a key insider may indicate confidence in the biotech firm, which specializes in developing targeted therapeutics for fibrotic diseases and cancer, and is currently progressing with several clinical trials.
For further insights into GB:REDX stock, check out TipRanks’ Stock Analysis page.
